Exendin-4 as a Treatment for Parkinson's Disease - Pilot Study

Exclusion Criteria

• •Diagnosis or suspicion of other cause for parkinsonism including Vascular parkinsonism, post traumatic parkinsonism, drug or toxin induced parkinsonism, or other neurodegenerative condition including Multiple System Atrophy, Progressive Supranuclear Palsy, Huntington's disease, Wilson's disease, Pantothenate kinase Neurodegeneration (PKAN), Alzheimer's disease, Creutzfeld Jacob disease.
• •Known abnormality on CT or MRI brain imaging considered to be causing symptoms or signs of neurological dysfunction, or considered likely to compromise compliance with trial protocol.
• •Concurrent dementia defined by a score lower than 120 on the Mattis Dementia Rating Scale.
• •Concurrent severe depression defined by a score greater than 16 on the MADRS Exposure to neuroleptic drugs within 6 months prior to baseline assessment Prior intracerebral surgical intervention for Parkinson's disease including Deep Brain stimulation, lesional surgery, growth factor administration, gene therapy or cell transplant
• •Already actively participating in a trial of a device, drug or surgical treatment for Parkinson's disease, or trial participation within previous 30 days.
• •Type 1 Diabetes mellitus
• •Type 2 Diabetes mellitus on insulin treatment
• •End stage renal disease or severely impaired renal function with creatinine clearance \<30ml/min
• •History of severe cardiac disease (Angina, Myocardial infarction or cardiac surgery in preceding 2 years)
• •History of pancreatitis
• •History of alcoholism
• •Severe gastrointestinal disease including gastroparesis
• •Ongoing treatment with sulphonylurea
• •Females that are pregnant or breast feeding or of child bearing potential.